Emergent BioSolutions discarded ingredients for 400 million COVID-19 vaccines, probe finds

Between March 2020 and February 2022, vaccine-maker Emergent BioSolutions was forced to discard or destroy up to 400 million doses’ worth of the key component of both Johnson & Johnson’s and AstraZeneca’s coronavirus vaccine due to quality-control issues, according to a congressional report published Tuesday — a figure that reflects more than five times what was previously disclosed by the beleaguered firm.

Problems included the contamination of vaccine ingredients, as well as equipment failures and employee errors, the report said.

Congressional investigators probing the Maryland-based biotech company found that Emergent executives had privately raised urgent quality-control concerns even before the company began manufacturing the vaccines’ key ingredient — despite publicly expressing confidence in their ability to deliver on their multimillion-dollar government contract .

Meanwhile, according to the report, Emergent lab workers intentionally sought to mislead government inspectors about issues at its Bayview, Maryland, plant, and repeatedly “rebuffed” efforts by AstraZeneca and Johnson & Johnson to inspect their facilities.

“Despite major red flags at its vaccine manufacturing facility, Emergent’s executives swept these problems under the rug and continued to rake in taxpayer dollars,” House Oversight and Reform Committee Chairwoman Carolyn Maloney, DN.Y., said of the report, which determined that the company’s “manufacturing failures and deceptive tactics” led to the large-scale waste of ingredients that could have helped make millions of vaccine doses.

None of the compromised batches of the ingredient in question made it into finished vaccine doses released from Emergent’s plant, the committees said.

Emergent spokesperson Matt Hartwig told ABC News that the company “refutes the allegation that it knowingly misled the FDA or any of our public and private partners,” saying that the firm had “sought to be overly transparent with all our manufacturing partners.”

“During the last few years, the FDA and other international regulatory authorities have visited Emergent facilities dozens of times,” Hartwig said. “On several occasions, Emergent invited FDA personnel to visit Bayview to review our progress, assess our capabilities, and provide feedback on our facilities, processes and systems when no FDA inspection was required.”

Tuesday’s joint report from the House Oversight Committee and the House Subcommittee on the Coronavirus Crisis aggregates the findings of their yearlong probe into Emergent’s quality control issues. As part of their efforts, committee investigators secured internal Emergent emails and interviewed several key witnesses, including senior officials from the US Food and Drug Administration.

Emergent landed a $628 million contract from the Biomedical Advanced Research and Development Authority in May 2020 to help develop Johnson & Johnson and AstraZeneca vaccines at its Bayview facility as part of Operation Warp Speed, the Trump administration’s rapid vaccine development program.

But according to the committees’ report, issues at Bayview arose even before the firm secured its vaccine-development deal. In a flurry of internal emails during the spring of 2020, executives and managers expressed a growing concern with the firm’s response to an April 2020 FDA audit that identified troubling safety deficiencies.

Sean Kirk, at the time an Emergent executive, wrote in a June 2020 email to a quality-control manager that the situation was “deeply concerning” and demanded that he “fix this.” In email correspondence with another colleague that same day, Kirk wrote that “room for improvement” in the Bayview plant’s quality control systems “is a huge understatement.”

Outwardly, however, the firm claimed its longstanding relationship with US government agencies — which included multiple contracts to develop anthrax vaccines — was evidence of its competence. But internally, said the report, alarm bells continued to sound — and anxiety over Bayview’s readiness grew.

“Of all the things we have to deliver on [Operation Warp Speed]the thing that keeps me up at night is overall perception of state of quality systems at bayview [sic],” Kirk wrote to Emergent CEO Robert Kramer in late June 2020.

The drumbeat of concern over quality control at Bayview reached a fever pitch in the fall of 2020, as internal memos ahead of a September 2020 FDA inspection indicated that executives were fully aware of gaps in quality control measures for months after vaccine development began, according to the congressional report.

“We are not in full compliance yet — BUT — we are making [vaccine] batches NOW,” Emergent’s senior director of quality wrote in an internal email, according to the report. “Our risk is high!”

In November 2020, according to an email obtained by the committees, a consultant with an outside firm warned the company that “ultimately Emergent will have to decide what level of risk they are willing to accept, but this is one of those where you really better listen to me and do exactly what I tell you to.”

“I am stating very loudly that this work is NON-compliant,” the consultant said. “And a direct regulatory risk.”

AstraZeneca representatives who visited Bayview in November 2020 complained that “a lack of fundamentals [was] contributing to bioburden issue,” and that “poor cleaning was part of the root cause” of the persistent contaminations, per the report.

Emergent executives acknowledged in internal emails that, in its rush to ramp up production, it hired temporary employees with “little or no pharmaceutical experience,” and described trash “piling up” in its facilities, said the report. FDA leaders told the committees that Emergent “hired a lot of individuals not as familiar with vaccine manufacturing, that did not have adequate training to do so” — a message it conveyed directly to Emergent as early as April 2020.

The committee found that despite these red flags, Emergent “did not remediate the issues, and problems persisted at the [Bayview] facility for months.” And from late 2020 to early 2021, the committee wrote, a series of contaminations at Bayview led to the disposal of enough vaccine drug ingredients to produce 240 million doses.

“The investigation has revealed that the impact of these issues is larger than previously known,” the committee said in its report, “with more incidents of contamination and millions more vaccines [ingredients] destroyed than previously revealed by Emergent.”

“The single contaminated batch was brought to the attention of the FDA by Johnson & Johnson and Emergent,” said Hartwig, the Emergent spokesperson. “The effort to manufacture two novel viral vaccine candidates in the same facility was unprecedented and potential risks were well known to all parties involved, including the FDA. It was for this reason that Emergent remained in constant communication with the FDA, BARDA and our clients every step of the way.”

In February 2021, under pressure from manufacturers to tighten up quality controls, Emergent apparently “rebuffed multiple requests from Johnson & Johnson’s quality staff to access Bayview,” the committee wrote. Around the same time, the committee found that Bayview lab workers sought to hide the extent of their failures prior to an FDA site visit.

According to an email written by one of Emergent’s external consultants and obtained by the committees, Emergent employees removed quality-assurance “hold tags” from two batches of Johnson & Johnson vaccine drug ingredients just one hour before FDA inspectors began their tour of the facility. The “hold tags” were bright yellow and indicated that those batches may have quality issues.

“Since the tags were deemed necessary before and after the FDA’s visit, it is my understanding, based on the entirety of what I observed and was told, that the purpose of removing the QA [quality assurance] hold tags was to avoid drawing attention to the two subject containers during the tour by the FDA inspectors,” the consultant wrote.

In their report, the committees indicated that senior leaders at Emergent were aware of the removal of the tags, and that the incident amounted to an “apparent attempt to impede oversight.” The FDA inspectors “still identified serious concerns” during their visit to the site in February 2021, but did not halt production at the facility until April 2021, after Emergent alerted the Biden administration to its cross-contamination incidents.

Dr. Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, told the committees in a briefing that FDA leaders and inspectors bore some responsibility for the extent of leniency they granted Emergent.

“Shame on us for thinking that [Emergent’s] experience in manufacturing would mean they would be able to move ahead and make the vaccines in a high-quality manner that we would expect for an experienced vaccine manufacturer,” Marks told committee members, according to the report.

In May 2021, during a hearing before the Congress, Emergent executives said the company hoped to resume production of the vaccines “in the coming days.” According to the committees, that didn’t happen; three months passed before regulators allowed Emergent to resume vaccine manufacturing in August 2021. But even then, the problems persisted.

From August 2021 to February 2022, the committee found that Emergent manufactured 15 new batches of Johnson & Johnson vaccine, six of which — the equivalent of 90 million vaccine doses — “were either aborted or rejected by Johnson & Johnson.”

All told, Emergent was forced to discard or destroy up to 400 million doses’ worth of the ingredient that helps make the coronavirus vaccine, according to the report. Company executives had previously pegged the number at 75 million.

Emerging representatives refuted the report’s characterization of the number of wasted doses of the key ingredient.

“It is very difficult to estimate dose equivalents for batches that do not complete the manufacturing process or leave the facility to be turned into vaccine,” Emergent spokesperson Hartwig said. “While unfortunate, a batch of drug substance may test out of specification for a variety of reasons whether during the manufacturing process or after the process is complete. … To equate these quality control actions with a ‘discarded dose’ figure displays a lack of understanding regarding the biomanufacturing process.”

In November 2021, the Biden administration canceled Emergent’s contract to continue developing vaccines, which at the time would have paid the company an estimated additional $320 million.

But the real victims, according to the committees, are those who would have benefitted from the 400 million doses that failed to materialize.

“Emergent’s failures wasted hundreds of millions of taxpayer dollars and impacted our country’s ability to meet the urgent, global need for coronavirus vaccines,” the report concludes.

The Emergent spokesperson told ABC News that the company “remains committed to being a trusted partner of the US and allied governments … [and] will continue to use our more than 20 years of public health preparedness experience to help inform an all-of-the-above approach to help prepare for the public health challenges to come.”

On Feb. 7 of this year, Emergent told the committees that its Bayview plant was entering a “maintenance shutdown period.” The company said it hopes to resume manufacturing in August 2022.

Emergent still maintains a federal contract to develop anthrax vaccines.

Source link

Leave a Comment

Your email address will not be published.